Glycine soya diet synergistically enhances the suppressive effect of tamoxifen and inhibits tamoxifen-promoted hepatocarcinogenesis in 7,12-dimethylbenz[α]anthracene-induced rat mammary tumor model

Food and Chemical Toxicology

Volumn 49, Issue 2, 2011, Pages 434-440

  Mishra, Rajeev ^a   Bhadauria, Smrati ^a   Murthy, P K ^a   Murthy, P S R ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Apoptosis; Glutathione S transferase; Glycine soya; Hepatocarcinogenesis; Proliferating cell nuclear antigen; Tamoxifen

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; DIMETHYLBENZ[A]ANTHRACENE; GLUTATHIONE TRANSFERASE; GLYCEROL; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG POTENTIATION; FEMALE; LIVER CANCER; LIVER CARCINOGENESIS; NONHUMAN; PLANT SEED; PRECANCER; PROTEIN EXPRESSION; RAT; SOYBEAN;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DIET; DRUG SYNERGISM; FEMALE; GLUTATHIONE S-TRANSFERASE PI; LIVER NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOYBEANS; TAMOXIFEN;

GLYCINE MAX; RATTUS;

EID: 78951486943     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.11.020     Document Type: Article

References (50)

1. Adlercreutz H. Lignans and human health. Crit. Rev. Clin. Lab. Sci. 2007, 44:483-525.
2. Adlercreutz H., Mazur W. Phyto-oestrogens and Western diseases. Ann. Med. 1997, 29:95-120.
3. Allred C.D., Allred K.F., Ju Y.H., Goeppinger T.S., Doerge D.R., Helferich W.G. Soy processing influences growth of estrogen-dependent breast cancer tumors. Carcinogenesis 2004, 25:1649-1657.
4. Appelt L.C., Reicks M.M. Soy feeding induces phase II enzymes in rat tissues. Nutr. Cancer 1997, 28:270-275.
5. Ariazi E.A., Ariazi J.L., Cordera F., Jordan V.C. Estrogen receptors as therapeutic targets in breast cancer. Curr. Top. Med. Chem. 2006, 6:181-202.
6. Bannasch P. Preneoplastic lesions as end points in carcinogenicity testing. II. Preneoplasia in various non-hepatic tissues. Carcinogenesis 1986, 7:849-852.
7. Bannasch P., Haertel T., Su Q. Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol. Pathol. 2003, 31:134-139.
8. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr. 1995, 125:777S-783S.
9. Barnes S., Grubbs C., Setchell K.D., Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. Prog. Clin. Biol. Res. 1990, 347:239-253.
10. Carthew P., Edwards R.E., Nolan B.M., Martin E.A., Heydon R.T., White I.N., Tucker M.J. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis 2000, 21:793-797.
11. Cederroth C.R., Nef S. Soy, phytoestrogens and metabolism: A review. Mol. Cell. Endocrinol. 2009, 304:30-42.
12. Chan P.C., Dao T.L. Enhancement of mammary carcinogenesis by a high-fat diet in Fischer, Long-Evans, and Sprague-Dawley rats. Cancer Res. 1981, 41:164-167.
13. Christov K., Ikui A., Shilkaitis A., Green A., Yao R., You M., Grubbs C., Steele V., Lubet R., Weinstein I.B. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res. Treat. 2003, 77:253-264.
14. Constantinou A.I., White B.E., Tonetti D., Yang Y., Liang W., Li W., van Breemen R.B. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur. J. Cancer 2005, 41:647-654.
15. Dragan Y.P., Xu Y.D., Pitot H.C. Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev. Med. 1991, 20:15-26.
16. Farber E. The sequential analysis of liver cancer induction. Biochim. Biophys. Acta 1980, 605:149-166.
17. Fournier D.B., Erdman J.W., Gordon G.B. Soy, its components, and cancer prevention: A review of the in vitro, animal, and human data. Cancer Epidemiol. Biomarkers Prev. 1998, 7:1055-1065.
18. Frairia R., Fortunati N., Fazzari A., Fissore F., Comba A., Becchis M., Catalano M.G., Benedusi-Pagliano E., Berta L., Mauro M., Gaidano G. Sex steroid binding protein is a negative modulator of estrogen-induced breast cancer cell growth. Ann. N. Y. Acad. Sci. 1996, 784:362-369.
19. Friedman M., Brandon D.L. Nutritional and health benefits of soy proteins. J. Agric. Food. Chem. 2001, 49:1069-1086.
20. Gallicchio L., Lord G., Tkaczuk K., Danton M., Lewis L.M., Lim C.K., Flaws J.A. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res. Treat. 2004, 85:89-97.
21. Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 1993, 53:3919-3924.
22. Haaparanta M., Paul R., Huovinen R., Kujari H., Bergman J., Solin O., Kangas L. Pharmacokinetics and metabolism of 2-[18F]fluoro-2-deoxy-D-glucose (FDG) in mammary tumors of antiestrogen-treated rats. Nucl. Med. Biol. 1995, 22:483-489.
23. Hard G.C., Iatropoulos M.J., Jordan K., Radi L., Kaltenberg O.P., Imondi A.R., Williams G.M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 1993, 53:4534-4541.
24. Helferich W.G., Andrade J.E., Hoagland M.S. Phytoestrogens and breast cancer: a complex story. Inflammopharmacol 2008, 16:219-226.
25. Ito N., Tatematsu M., Nakanishi K., Hasegawa R., Takano T., Imaida K., Ogiso T. The effects of various chemicals on the development of hyperplastic liver nodules in hepatectomized rats treated with N-nitrosodiethylamine or N-2-fluorenylacetamide. Gann 1980, 71:832-842.
26. Jordan, V.C. (2006). Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br. J. Pharmacol. 147 Suppl 1, S269-S276.
27. Jordan V.C., Murphy C.S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 1990, 11:578-610.
28. Kerwin S.M. Soy saponins and the anticancer effects of soybeans and soy-based foods. Curr. Med. Chem. Anticancer Agents 2004, 4:263-272.
29. Kim D.J., Han B.S., Ahn B., Lee K.K., Kang J.S., Tsuda H. Promotion potential of tamoxifen on hepatocarcinogenesis in female SD or F344 rats initiated with diethylnitrosamine. Cancer Lett. 1996, 104:13-19.
30. Kishida T., Nashiki K., Izumi T., Ebihara K. Soy isoflavonoid aglycons genistein and daidzein Do not increase the cytochrome P-450 content of the liver microsomes of mice. J. Agric. Food. Chem. 2000, 48:3872-3875.
31. Kurzer M.S., Xu X. Dietary phytoestrogens. Annu. Rev. Nutr. 1997, 17:353-381.
32. Lee K.W., Wang H.J., Murphy P.A., Hendrich S. Soybean isoflavone extract suppresses early but not later promotion of hepatocarcinogenesis by phenobarbital in female rat liver. Nutr. Cancer 1995, 24:267-278.
33. Lei B., Roncaglia V., Vigano R., Cremonini C., De M.N., Del Buono M.G., Manenti F., Villa E. Phytoestrogens and liver disease. Mol. Cell. Endocrinol. 2002, 193:81-84.
34. Matsumoto H., Koibuchi Y., Horiguchi J., Iino Y., Morishita Y. Combined effects of lutenizing hormone-releasing hormone analogue with antiestrogen on rat mammary tumors. Oncol. Rep. 2002, 9:145-151.
35. Mense S.M., Hei T.K., Ganju R.K., Bhat H.K. Phytoestrogens and breast cancer prevention: Possible mechanisms of action. Environ. Health Perspect. 2008, 116:426-433.
36. Mishra R., Tiwari A., Bhadauria S., Mishra J., Murthy P.K., Murthy P.S. Therapeutic effect of centchroman alone and in combination with glycine soya on 7, 12-dimethylbenz[alpha]anthracene-induced breast tumor in rat. Food Chem. Toxicol. 2010, 48:1587-1591.
37. Nelson D., Ganss R. Tumor growth or regression: Powered by inflammation. J. Leukoc. Biol. 2006, 80:685-690.
38. Patel R.R., Sengupta S., Kim H.R., Klein-Szanto A.J., Pyle J.R., Zhu F., Li T., Ross E.A., Oseni S., Fargnoli J., Jordan V.C. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors. Eur. J. Cancer 2010, 46:1537-1553.
39. Russo J., Gusterson B.A., Rogers A.E., Russo I.H., Wellings S.R., van Zwieten M.J. Comparative study of human and rat mammary tumorigenesis. Lab. Invest. 1990, 62:244-278.
40. Sakai M., Muramatsu M. Regulation of glutathione transferase P: A tumor marker of hepatocarcinogenesis. Biochem. Biophys. Res. Commun. 2007, 357:575-578.
41. Seielstad D.A., Carlson K.E., Kushner P.J., Greene G.L., Katzenellenbogen J.A. Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis. Biochemistry 1995, 34:12605-12615.
42. Shagufta, Srivastava A.K., Sharma R., Mishra R., Balapure A.K., Murthy P.S., Panda G. Substituted phenanthrenes with basic amino side chains: A new series of anti-breast cancer agents. Bioorg. Med. Chem. 2006, 14:1497-1505.
43. Shimomura M., Higashi S., Mizumoto R. 32P-postlabeling analysis of DNA adducts in rats during estrogen-induced hepatocarcinogenesis and effect of tamoxifen on DNA adduct level. Jpn. J. Cancer Res. 1992, 83:438-444.
44. Tatematsu M., Tsuda H., Shirai T., Masui T., Ito N. Placental glutathione S-transferase (GST-P) as a new marker for hepatocarcinogenesis: In vivo short-term screening for hepatocarcinogens. Toxicol. Pathol. 1987, 15:60-68.
45. Trock B.J., Hilakivi-Clarke L., Clarke R. Meta-analysis of soy intake and breast cancer risk. J. Natl Cancer Inst. 2006, 98:459-471.
46. Tsuda H., Farber E. Resistant hepatocytes as early changes in liver induced by polycyclic aromatic hydrocarbons. Int. J. Cancer 1980, 25:137-139.
47. Tsuda H., Lee G., Farber E. Induction of resistant hepatocytes as a new principle for a possible short-term in vivo test for carcinogens. Cancer Res. 1980, 40:1157-1164.
48. van Leeuwen F.E., Benraadt J., Coebergh J.W., Kiemeney L.A., Gimbrere C.H., Otter R., Schouten L.J., Damhuis R.A., Bontenbal M., Diepenhorst F.W. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994, 343:448-452.
49. Williams G.M., Iatropoulos M.J., Djordjevic M.V., Kaltenberg O.P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993, 14:315-317.
50. Yamada K., Ito A., Watanabe H., Takahashi T., Basaran N.H., Gotoh T. High sensitivity to hepato-tumorigenesis in hypocatalasemic C3H/C(s)b/Gen mice exposed to low doses of 252Cf fission neutrons and 60Co gamma-rays. Anticancer Res. 1997, 17:2041-2047.